Select from the dropdown list to complete the text.
In a long-term (25 month) followup, 79% of patients treated with Oxilaplatin reported persistent neuropathic symptoms. Of these, those with the most severe neuropathy at followup had displayed the ( Greatest, Least ) excitability change during treatment.